Mittal Ankit, Raber Anne S, Lehr Claus-Michael, Hansen Steffi
Biopharmaceutics and Pharmaceutical Technology; Saarland University; Saarbruecken, Germany.
Hum Vaccin Immunother. 2013 Sep;9(9):1950-5. doi: 10.4161/hv.25217. Epub 2013 Jun 18.
Vaccine formulations on the basis of nano- (NP) or microparticles (MP) can solve issues with stabilization, controlled release, and poor immunogenicity of antigens. Likewise transcutaneous immunization (TCI) promises superior immunogenicity as well as the advantages of needle-free application compared with conventional intramuscular injections. Thus the combination of both strategies seems to be a very valuable approach. However, until now TCI using particle based vaccine formulations has made no impact on medical practice. One of the main difficulties is that NPs and MPs cannot penetrate the skin to an extent that would allow the application of the required dose of antigen. This is due to the formidable stratum corneum (SC) barrier, the limited amount of antigen in the formulation and often an insufficient immunogenicity. A multitude of strategies are currently under investigation to overcome these issues. We highlight selected methods presenting a spectrum of solutions ranging from transfollicular delivery, to devices disrupting the SC barrier and the combination of particle based vaccines with adjuvants discussing their advantages and shortcomings. Some of these are currently at an experimental state while others are already in clinical testing. All methods have been shown to be capable of transcutaneous antigen delivery.
基于纳米颗粒(NP)或微粒(MP)的疫苗制剂可以解决抗原的稳定性、控释和免疫原性差等问题。同样,与传统的肌肉注射相比,经皮免疫(TCI)具有卓越的免疫原性以及无针接种的优势。因此,将这两种策略结合起来似乎是一种非常有价值的方法。然而,到目前为止,使用基于颗粒的疫苗制剂进行经皮免疫尚未对医疗实践产生影响。主要困难之一是纳米颗粒和微粒无法穿透皮肤至能施用所需剂量抗原的程度。这是由于强大的角质层(SC)屏障、制剂中抗原量有限以及免疫原性往往不足所致。目前正在研究多种策略来克服这些问题。我们重点介绍了一些选定的方法,这些方法展示了一系列解决方案,从经毛囊递送、破坏角质层屏障的装置,到基于颗粒的疫苗与佐剂的组合,并讨论了它们的优缺点。其中一些目前处于实验阶段,而另一些已经在进行临床试验。所有这些方法都已被证明能够实现经皮抗原递送。